NIH Discourages Off-Patent Drugs While Collecting Royalties on New Products! - Rep. John Moolenaar

Rep. John Moolenaar Asks Why NIH Leaders are Allowed to Discourage Use of Off-Patent Drugs While Collecting Royalties on New Products

“What strikes me is you’re in a position where you say certain drugs don’t work, but then you can at the same time be getting royalties from other products.”

*From the 2023 NIH Budget Hearing in May 2022